BBOT (STOCKS)
BridgeBio Oncology Therapeutics, Inc. Common Stock
$9.340000
-0.080000 (-0.85%)
Prev close: $9.420000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Pedro J. Beltran
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $846.79M
- Employees
- 92
- P/E (TTM)
- -0.01
- P/B (TTM)
- 2.34
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.53 | $-0.54 | +0.0075 | +1.40% |
|
Dec 2025 (Q4)
|
$-0.49 | $-0.53 | +0.0375 | +7.11% |
|
Sep 2025 (Q3)
|
$-1.03 | $-0.40 | -0.6324 | -159.05% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $16.84M |
| Operating Expenses | $198.96M |
| Research and Development | $162.15M |
| Other Operating Expenses | $36.80M |
| Operating Income/Loss | -$198.96M |
| Income/Loss From Continuing Operations After Tax | -$182.11M |
| Income/Loss From Continuing Operations Before Tax | -$182.11M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$182.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$182.11M |
| Net Income/Loss Available To Common Stockholders, Basic | -$182.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.23K |
| Diluted Earnings Per Share | -$1.23K |
| Basic Average Shares | 140,022,870 |
| Diluted Average Shares | 140,022,870 |
| Assets | $376.71M |
| Current Assets | $242.38M |
| Cash | $344.10M |
| Noncurrent Assets | $134.33M |
| Fixed Assets | $878.00K |
| Other Non-current Assets | $133.45M |
| Liabilities | $53.59M |
| Current Liabilities | $51.63M |
| Accounts Payable | $6.73M |
| Other Current Liabilities | $44.91M |
| Noncurrent Liabilities | $1.96M |
| Equity | $323.11M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $323.11M |
| Liabilities And Equity | $376.71M |
| Net Cash Flow From Operating Activities | -$151.28M |
| Net Cash Flow From Operating Activities, Continuing | -$151.28M |
| Net Cash Flow From Investing Activities | -$191.36M |
| Net Cash Flow From Investing Activities, Continuing | -$191.36M |
| Net Cash Flow From Financing Activities | $365.18M |
| Net Cash Flow From Financing Activities, Continuing | $365.18M |
| Net Cash Flow | $22.55M |
| Net Cash Flow, Continuing | $22.55M |
| Comprehensive Income/Loss | -$183.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$183.12M |
| Other Comprehensive Income/Loss | -$183.12M |